Cyclacel Pharmaceuticals Inc (NAS:CYCC)
$ 2.34 -0.1 (-4.1%) Market Cap: 3.42 Mil Enterprise Value: 229,000.00 PE Ratio: 0 PB Ratio: 4.09 GF Score: 28/100

Cyclacel Pharmaceuticals Inc Research & Development Day Transcript

Oct 31, 2022 / 02:00PM GMT
Release Date Price: $20.85 (-2.11%)
Tara Sobierajski

Good morning, and welcome to the Cyclacel Pharmaceuticals' R&D Day. (Operator Instructions) If you'd like to submit a question, you may do so by using the Q&A text box at the bottom of the webcast player or by e-mailing your questions to [email protected].

As a reminder, this call is being recorded and a replay will be made available on the Cyclacel's website following the conclusion of the event. I'd now like to turn the call over to Spiro Rombotis, President and Chief Executive Officer of Cyclacel Pharmaceuticals. Please go ahead, Spiro.

Spiro George Rombotis
Cyclacel Pharmaceuticals, Inc. - President, CEO & Executive Director

Thank you, Tara, and good morning, everyone. Let me also extend a warm welcome to those of you who'll be listening by webcast. Before I make my further remarks and so would my colleagues, I would like to draw your attention to the usual disclaimer regarding forward-looking statements we will be making about our programs, which are subject to change. And I would refer you to our filings with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot